Shuo Kang

5PUBLICATIONS
2CO-AUTHORS
Economic models and forecastingCancer therapy (excl. chemotherapy and radiation therapy)Cross-sectional analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 21, 2025
Cost effectiveness and pricing strategy of first line benmelstobart combination treatment for extensive stage small cell lung cancer in China.

Shan Zhao, Shuo Kang

|Jul 24, 2025
Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China.

Shuo Kang, Shan Zhao, Xiaohui Wang

|Mar 26, 2025
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China.

Shan Zhao, Shuo Kang

|Mar 20, 2024
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis.

Shuo Kang, Jintuo Yin

|Nov 08, 2023
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.

Shuo Kang, Huanlong Liu

Pageof 1

Frequent Collaborators

1 joint publications

Huanlong Liu

1 joint publications

Zhenhua Pan